HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Isradipine

HCID 3784
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
75695-93-1
Standard SMILES
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12
InChIKey
HMJIYCCIJYRONP-UHFFFAOYSA-N
Molecular formula
C19H21N3O5
Average molar mass
371.4 g/mol
Monoisotopic mass
371.14812078

Overview

Isradipine is a methyl ester, an isopropyl ester, a benzoxadiazole and a dihydropyridine.

Names & identifiers

Preferred name
Isradipine
IUPAC
3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
English name
Isradipine
Molecular formula
C19H21N3O5
Molecular weight
371.39

Names & synonyms

isradipine75695-93-1DynaCircLomirPrescalDynacirc CRPN 200-110IsradipinoIsradipinumPN-200-110DTXSID4023179isradipina
Show more names
IomirPrescaCS-139EsradinRebfidenClivotenDynacrine
PN 205-033NSC-759892YO1UK1S5983,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl esterPN 2050343,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl esterDTXCID203179O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

Database identifiers

CAS
75695-93-1
PubChem CID
3784
DTXSID
DTXSID4023179
ChEMBL
CHEMBL1648、CHEMBL315436、CHEMBL3211306
ChEBI
CHEBI:6073
UNII
YO1UK1S598
EC Number
630-420-5
Nikkaji
J33.142B、J356.392H、J356.393F

Properties

Computed structural properties

XLogP
4.3
Topological polar surface area
104 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
8
Rotatable bonds
6
Heavy atoms
27
Formal charge
0
Complexity
685

Experimental & physicochemical properties

DrugsPharmaceuticals
LogP2.901
Solubility · 2 items

Practically insoluble (< 10 mg/L at 37 °C)

2.28e-01 g/L

Human Drugs · 4 items

Breast Feeding; Lactation; Antihypertensive Agents; Calcium Channel Blockers; Vasodilator Agents;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2 items

168-170 °C

168 - 170 °C

Physical DescriptionSolid

Physicochemical properties

Melting point
166 · 166-1680C
Boiling point
501.9 · 501.9±60.0 °C(Predicted)
Density
1.249 · 1.249±0.06 g/cm3(Predicted)
storage temp.

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (98%): Toxic if swallowed [Danger Acute toxicity, oral]

P260, P264, P264+P265, P270, P273, P280, P301+P316, P305+P351+P338, P319, P321, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 51 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (98%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Isradipine

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
hs_code
2934990002
Signal word
Warning
Symbol(GHS)
GHS07
safety_code
22-24/25
Storage Class
11 - Combustible Solids
Hazard statements
H413

Chemistry & industry

Pharmacology

ATC Code · 2 items

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding95%
Pharmacodynamics · 1 item

Isradipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of isradipine result in an overall decrease in blood pressure.

Mechanism of Action · 1 item

Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in <i>Homo sapiens</i>: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, isradipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives isradipine additional arterial selectivity. At therapeutic sub-toxic concentrations, isradipine has little effect on cardiac myocytes and conduction cells.

Biological Half-Life8 hours
Metabolism/MetabolitesHepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine.

Related reactions

4 records
New reaction record
HRID 1387604 reaction equation
HRID 1387604As reactant
HRID 2054702 reaction equation
HRID 2054702As reactant
HRID 2054703 reaction equation
HRID 2054703As product
HRID 2054706 reaction equation
HRID 2054706As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
2 · 2-8°C
solubility
26 mg/mL · DMSO: ~26 mg/mL
form
solid
pka
2.56 · 2.56±0.70(Predicted)
color
yellow
Merck
14 · 14,5240
BCS Class
2 · 2/4
Stability
2 years · Stable for 2 years from date of purchsae as supplied. Protect from moisture. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
Major Application
pharmaceutical (small molecule)
InChI
InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChIKey
HMJIYCCIJYRONP-UHFFFAOYSA-N
SMILES
C1(C)NC(C)=C(C(OC(C)C)=O)C(C2C3C(C=CC=2)=NON=3)C=1C(OC)=O
CAS DataBase Reference
75695 · 75695-93-1(CAS DataBase Reference)
FDA UNII
1 UK1S598 · YO1UK1S598
ATC code
8 CA03 · C08CA03
NIST Chemistry Reference
Isradipine(75695-93-1)
Comptox DTXSID
4023179 · DTXSID4023179
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
413 · H413
Precautionary statements
501 · P501-P273
Safety Statements
22 · 22-24/25
WGK Germany
3 · 3
HS Code
2934990002 · 2934990002
Storage Class
11 · 11 - Combustible Solids
Precautionary statements
P501-P273
FDA Pharmacological Classification · 6 items

YO1UK1S598

ISRADIPINE

Mechanisms of Action [MoA] - Calcium Channel Antagonists

Established Pharmacologic Class [EPC] - Dihydropyridine Calcium Channel Blocker

Chemical Structure [CS] - Dihydropyridines

Isradipine is a Dihydropyridine Calcium Channel Blocker. The mechanism of action of isradipine is as a Calcium Channel Antagonist.

MeSH Pharmacological Classification · 3 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

A class of drugs that act by selective inhibition of calcium influx through cellular membranes.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and Excretion · 2 items

Isradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%.

Approximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces.

Cellular LocationsMembrane
Metabolite PathwaysIsradipine Action Pathway

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >10
Use ClassificationPharmaceuticals
Applications · 5 items

DescriptionIsradipine is a long-acting calcium blocker effective in the treatment of essential hypertension. The advantages of isradipine as compared with other dihydropyridine calcium antagonists include a "gentle" onset and fewer contraindications. It can be taken by patients with diabetes mellitus, chronic obstructive airway diseases, gout, congestive heart failure or ischemic heart disease.

UsesIsradipine is a L-type calcium channel blocker, Isradipine has anti-atherosclerotic effects in animals and improves endothelium-mediated nitric oxide (NO)-dependent vasodilation in vitro. Additional studies indicate that Isradipine may provide a neuroprotective effect in a rat model of focal ischemia and that Isradipine produces a dose-dependent sparing of dopamine neuronal fibers and cell bodies.

Usesnonsedating H1-antihistamine

UsesDihydropyridine calcium channel blocker. Antihypertensive; antianginal

General DescriptionIsradipine, 4-(4-benzofuranazyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester (DynaCirc), is another second-generationdihydropyridine-type channel blocker. This drug, like theother second-generation analogs, is more selective for vascularsmooth muscle than for myocardial tissue. It is effectivein the treatment of stable angina, reducing the frequencyof anginal attacks and the need to use nitroglycerin.

Upstream & downstream products

Upstream raw materials

Isopropyl acetoacetateBenzofuroxanMethyl 3-aminocrotonate

Additional notes

DefinitionChEBI: Isradipine is an isopropyl ester, a methyl ester, a dihydropyridine and a benzoxadiazole.